

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zhongzhi Pharmaceutical Holdings Limited

中智藥業控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3737)

POLL RESULT OF 2023 EXTRAORDINARY GENERAL MEETING

The Board is pleased to announce that the resolution proposed at the EGM held on 13 October 2023 were duly passed by the Shareholders by way of poll at the EGM.

Reference is made to the notice of extraordinary general meeting (the “**EGM**”) and the circular of the Company (the “**Circular**”) both dated 19 September 2023. Capitalized terms used herein shall have the same meanings as defined in the Circular unless the context requires otherwise.

The Board is pleased to announce that the proposed resolution as set out in the notice of EGM dated 19 September 2023 were duly passed by the Shareholders by way of poll at the EGM held on 13 October 2023.

As at the date of the EGM, the total number of Shares in the issued share capital of the Company was 863,600,000 Shares. There were no Shares entitling the Shareholders to attend and abstain from voting in favour of the resolution proposed at the EGM. None of the Shareholders were required to abstain from voting at the EGM. Accordingly, there were a total of 863,600,000 Shares, representing the entire issued share capital of the Company, entitling the Shareholders to attend and vote for or against the resolution proposed at the EGM. No Shareholders has stated their intention in the Circular to vote against or to abstain from voting on the resolution at the EGM.

The Company’s branch share registrar and transfer office in Hong Kong, Union Registrars Limited, was appointed as the scrutineer at the EGM for the purpose of vote-taking.

The poll result in respect of the resolution at the EGM are set out as follows:

ORDINARY RESOLUTION		Number of Votes (approx. %)	
		FOR	AGAINST
1.	<p>(a) the declaration and payment of an interim dividend of HK6 cents per ordinary share out of the share premium account of the Company (the “Interim Dividend”) to shareholders of the Company whose names appear on the register of members of the Company on the record date fixed by the board of Directors for determining the entitlements to the Interim Dividend be and is hereby approved; and</p> <p>(b) any Director of the Company be and is hereby authorised to take such action, do such things and execute such further documents as the director may at his absolute discretion consider necessary or desirable for the purpose of or in connection with the implementation of the payment of the Interim Dividend.</p>	567,122,000 (100.00%)	0 (0.00%)

As more than 50% of the votes were cast in favour of the resolution no.1, the resolution no.1 was duly passed as ordinary resolution of the Company.

All Directors attended the EGM accordingly.

By order of the Board
Zhongzhi Pharmaceutical Holdings Limited
Mr. Lai Zhi Tian
Chairman and Executive Director

Hong Kong, 13 October 2023

As at the date of this announcement, the Board comprises nine directors. The executive directors are Mr. Lai Zhi Tian, Mr. Lai Ying Feng, Mr. Lai Ying Sheng and Mr. Cao Xiao Jun. The non-executive directors are Ms. Jiang Li Xia and Mr. Peng Zhiyun. The independent non-executive directors are Mr. Ng Kwun Wan, Mr. Wong Kam Wah and Mr. Zhou Dai Han.